المؤلفون: Boscolo Bielo L; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Belli C; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy., Crimini E; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Repetto M; Early Drug Development Service, Memorial Sloan Kettering Cancer Center, New York, USA., Ascione L; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Pellizzari G; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Santoro C; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Fuorivia V; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Barberis M; Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy., Fusco N; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy., Rocco EG; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy., Curigliano G; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

المصدر: The oncologist [Oncologist] 2024 Jun 03; Vol. 29 (6), pp. 504-510.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms, Unknown Primary*/genetics , Neoplasms, Unknown Primary*/drug therapy , Neoplasms, Unknown Primary*/pathology , Genomics*/methods, Humans ; Male ; Female ; Middle Aged ; Aged ; Retrospective Studies ; High-Throughput Nucleotide Sequencing/methods ; Adult ; Aged, 80 and over ; Mutation ; Europe

المؤلفون: Katrini J; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Boldrini L; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Santoro C; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Valenza C; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Trapani D; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Curigliano G; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2024 Apr 02; Vol. 23 (4), pp. 436-446.

نوع المنشور: Review; Journal Article

بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Immunoconjugates*/pharmacology , Immunoconjugates*/therapeutic use , Neoplasms* , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/therapeutic use, Humans ; Quality of Life ; Biomarkers

المؤلفون: Valenza C; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., De Pas TM; Medical Oncology Division, Cliniche Humanitas Gavazzeni, Bergamo, Italy., Gaeta A; Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milan, Italy., Castellano G; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Santoro C; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Corona A; Division of Melanoma, Soft Tissue Sarcomas and Rare Tumors, European Institute of Oncology, IRCCS, Milan, Italy., Chiappini G; Division of Melanoma, Soft Tissue Sarcomas and Rare Tumors, European Institute of Oncology, IRCCS, Milan, Italy., Vivanet G; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Trapani D; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Coppola S; Division of Melanoma, Soft Tissue Sarcomas and Rare Tumors, European Institute of Oncology, IRCCS, Milan, Italy., Conforti F; Medical Oncology Division, Cliniche Humanitas Gavazzeni, Bergamo, Italy., Mattar D; Division of Breast Surgery, European Institute of Oncology, IRCCS, Milan, Italy., Gandini S; Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milan, Italy., Veronesi P; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Division of Breast Surgery, European Institute of Oncology, IRCCS, Milan, Italy., Pennacchioli E; Division of Melanoma, Soft Tissue Sarcomas and Rare Tumors, European Institute of Oncology, IRCCS, Milan, Italy., Curigliano G; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Jan; Vol. 196, pp. 113423. Date of Electronic Publication: 2023 Nov 10.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/surgery , Phyllodes Tumor*/surgery , Phyllodes Tumor*/pathology, Humans ; Female ; Mastectomy ; Retrospective Studies ; Neoplasm Recurrence, Local/epidemiology ; Breast/pathology

المؤلفون: Kotteas E; Oncology Unit, 3rd Department of Internal Medicine, National & Kapodistrian University of Athens, Athens, Greece., Bielo LB; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Valenza C; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Santoro C; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Koukoutzeli C; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy., Trapani D; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Curigliano G; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

المصدر: Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2023 Jul-Dec; Vol. 23 (10), pp. 1107-1116. Date of Electronic Publication: 2023 Oct 26.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101123358 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8328 (Electronic) Linking ISSN: 14737140 NLM ISO Abbreviation: Expert Rev Anticancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Triple Negative Breast Neoplasms*/pathology, Humans ; Quality of Life ; Prognosis ; Neoadjuvant Therapy ; Biomarkers

المؤلفون: Valenza C; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy.; Department of Oncology and Hematology-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy., Taurelli Salimbeni B; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy.; Department of Clinical and Molecular Medicine, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy., Santoro C; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy.; Department of Oncology and Hematology-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy., Trapani D; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy.; Department of Oncology and Hematology-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy., Antonarelli G; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy.; Department of Oncology and Hematology-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy., Curigliano G; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy.; Department of Oncology and Hematology-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy.

المصدر: Cancers [Cancers (Basel)] 2023 Jan 26; Vol. 15 (3). Date of Electronic Publication: 2023 Jan 26.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

المؤلفون: Attili I; Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy., Valenza C; Division of New Drug Development, European Institute of Oncology IRCCS, Milan, Italy.; Università degli Studi di Milano, Department of Oncology and Hemato-Oncology, Milan, Italy., Santoro C; Division of New Drug Development, European Institute of Oncology IRCCS, Milan, Italy.; Università degli Studi di Milano, Department of Oncology and Hemato-Oncology, Milan, Italy., Antonarelli G; Division of New Drug Development, European Institute of Oncology IRCCS, Milan, Italy.; Università degli Studi di Milano, Department of Oncology and Hemato-Oncology, Milan, Italy., Trillo Aliaga P; Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy., Del Signore E; Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy., Catania C; Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy., Spitaleri G; Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy., Passaro A; Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy., de Marinis F; Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy.

المصدر: Frontiers in oncology [Front Oncol] 2022 Aug 10; Vol. 12, pp. 980765. Date of Electronic Publication: 2022 Aug 10 (Print Publication: 2022).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE